Greenstone Biosciences Analysis: $20M Raised
What is Greenstone Biosciences?
AI-powered iPSC platform for human-relevant drug discovery
Location
Palo Alto, United States
Employees
11-50
Founded
2022
Product Features & Capabilities
- hiPSC-Derived Cells
- Ventricular Cardiomyocytes
- Atrial Cardiomyocytes
- Fibroblasts
- Smooth Muscle Cells
- Macrophages
- Endothelial Cells
- Organoids
- Vascularized Ventricular Cardiac Organoid
- Vascularized Atrial Cardiac Organoid
- Pancreatic Islet Organoid
- Gut Organoid
- PBMC Collection and iPSC Reprogramming
- Custom Differentiated iPSCs
- Genetically Engineered iPSCs
- High-throughput Drug Discovery
- Cell Village
- Clinical Trial in a Dish
- CARTOX (hERG Toxicity Assay)
- Hepatotoxicity Screen
- Gut Organoid Permeability Assay
- Pancreatic Islet Organoid – Glucose Sensitivity
Use Cases
Model cardiac diseases using patient-derived cardiomyocytes; Screen for cardiotoxicity using ADMET-AI; Test drug efficacy in pancreatic islet organoids; Evaluate gut permeability in organoid models; Perform hepatotoxicity screening; Conduct CRISPRi/a screens in human iPSC-cardiomyocytes
Other Considerations
Co-founded by Dr. Joseph C. Wu (Stanford); Published in Nature and Circulation; Proprietary ADMET-AI algorithm for cardiotoxicity prediction; Offers patient-specific disease modeling; Provides human-relevant, animal-free drug testing platforms
See something that needs updating? Suggest edits to this profile.